Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial - Inria - Institut national de recherche en sciences et technologies du numérique
Article Dans Une Revue Annals of Oncology Année : 2019

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Daniel Pissaloux
  • Fonction : Auteur
  • PersonId : 768539
  • IdRef : 17847147X
Isabelle Ray-Coquard
Thomas Bachelot
Sandrine Boyault
  • Fonction : Auteur
  • PersonId : 757688
  • IdRef : 075706466

Résumé

Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological subtypes. We aim to explore the feasibility, efficacy and therapeutic impact of molecular profiling in routine setting.

Dates et versions

hal-02367110 , version 1 (17-11-2019)

Identifiants

Citer

Olivier Trédan, Qiang Wang, Daniel Pissaloux, Pierre Cassier, Arnaud de La Fouchardière, et al.. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Annals of Oncology, 2019, 30 (5), pp.757-765. ⟨10.1093/annonc/mdz080⟩. ⟨hal-02367110⟩
180 Consultations
0 Téléchargements

Altmetric

Partager

More